Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE‐052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The purpose of the present two phase 1 studies was to assess the safety, tolerability and pharmacokinetics for topical application of a novel Janus kinase (JAK) inhibitor, JTE‐052, in Japanese healthy adult male volunteers and Japanese adult patients with atopic dermatitis (AD). Additionally, exploratory investigation was performed on the efficacy for disease severity and pruritus score in AD patients. In the QBX 1‐1 study, the cutaneous safety of JTE‐052 ointment by a patch test and a photo patch test was assessed in an intra‐individual comparative study using placebo ointment, white petrolatum and non‐application as comparators. The study demonstrated that JTE‐052 ointment would be associated with a low potential for phototoxicity but had no potential for skin irritation or photoallergy. In the QBX 1‐2 study, it was revealed that the systemic exposure to JTE‐052 in both healthy volunteers with normal skin and AD patients with inflamed skin was low in application of not only 1% but also 3% JTE‐052 ointment. JTE‐052 ointments of 1% and 3% were generally safe and well tolerated in both populations. In a repeated twice‐daily application for 7 days, the efficacy of JTE‐052 ointment to AD patients was observed with both 1% and 3% ointments in the exploratory investigations evaluated by Eczema Area and Severity Index, Investigator's Global Assessment and Numeric Rating Scale assessments. The mean scores for each assessment declined from the baseline throughout the study. These results suggest that the treatment of JTE‐052 ointment is generally safe and effective in AD patients, although further large confirmatory studies are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch
Oetjen, L. K., Mack, M. R., Feng, J., Whelan, T. M., Niu, H., Guo, C. J., Chen, S., Trier, A. M., Xu, A. Z., Tripathi, S. V., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.006 · Cited by 1,092
Amano, W., Nakajima, S., Kunugi, H., Numata, Y., Kitoh, A., Egawa, G., Dainichi, T., Honda, T., Otsuka, A., Kimoto, Y., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.03.051 · Cited by 259
Tanimoto, A., Ogawa, Y., Oki, C., Kimoto, Y., Nozawa, K., Amano, W., Noji, S., Shiozaki, M., Matsuo, A., Shinozaki, Y., et al. (2015) · Inflammation Research · doi:10.1007/s00011-014-0782-9 · Cited by 111
Cited by
A Comprehensive Overview of Globally Approved JAK Inhibitors
Shawky, A. M., Almalki, F. A., Abdalla, A. N., Abdelazeem, A. H., & Gouda, A. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051001 · Cited by 349
Itch: From mechanism to (novel) therapeutic approaches
Yosipovitch, G., Rosen, J. D., & Hashimoto, T. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.09.005 · Cited by 343
Emerging Topical and Systemic JAK Inhibitors in Dermatology
Solimani, F., Meier, K., & Ghoreschi, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02847 · Cited by 308
Physiology and Pathophysiology of Itch
Cevikbas, F., & Lerner, E. A. (2020) · Physiological Reviews · doi:10.1152/physrev.00017.2019 · Cited by 282
Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Kaino, H., & Nagata, T. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.12.015 · Cited by 242
“Previous studies showed the potential effectiveness of delgocitinib ointment in Japanese adult patients with AD.(29,30) In the present phase 3 study, we evaluated the efficacy and safety of delgocitinib 0.”
BackgroundSelf-citation
Metadata
- Authors
- Nakagawa, H., Nemoto, O., Yamada, H., Nagata, T., & Ninomiya, N.
- Venue
- The Journal of Dermatology
- Publisher
- Wiley
- Published
- 2018-04-17
- Volume
- 45
- Issue
- 6
- Pages
- 701-709
- ISSN
- 0385-2407 (ISSN-L)
- 1346-8138
- OpenAlex
- W2799381018
- Cited by
- 49
- References
- 4
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.